ReviewiLIVER2022
Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review.
Review in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Nomogram predicting outcomes in HCC patients treated with TACE-HAIC, TKIs, and PD-1 inhibitors.World journal of surgical oncology · 2026Article
- LINC01305 and LAD1 Co-Regulate CTTN and N-WASP Phosphorylation, Mediating Cytoskeletal Reorganization to Promote ESCC Metastasis.Molecular carcinogenesis · 2025Article
- PD1Cancer immunology, immunotherapy : CII · 2025Article
- The effectiveness of problem-based learning and case-based learning teaching methods in clinical practical teaching in TACE treatment for hepatocellular carcinoma in China: a bayesian network meta-analysis.BMC medical education · 2024Article
- Coexistence of liver abscess, hepatic cystic echinococcosis and hepatocellular carcinoma: A case report.World journal of clinical cases · 2024Article
- Article
- Transarterial Chemoembolization Plus Sorafenib versus Transarterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses and Systematic Reviews.Journal of hepatocellular carcinoma · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. With the development of systemic therapies, several studies are currently underway, especially those related to the use of programmed death-1/programmed cell death-ligand 1 (PD-1/PD-L1) immunotherapy. Moreover, studies on transarterial chemoembolization (TACE) and PD-1/PD-L1 immunotherapy have demonstrated some interesting outcomes. This article reviewed the current clinical evidence on the combination of TACE and PD-1/PD-L1 immunotherapy. Overall, our review summarized that a favorable survival time could be achieved using this combination in most patients. However, complications such as hyperprogression should be taken seriously, and the underlying mechanisms need to be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.